We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
Bristol Myers Squibb Co | NYSE:BMY | NYSE | Common Stock |
Price Change | % Change | Share Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|
-0.5099 | -1.15% | 43.7001 | 44.42 | 43.333 | 44.38 | 15,962,876 | 01:00:00 |
By Chris Wack
Bristol Myers Squibb said the U.S. Food and Drug Administration has accepted for priority review its supplemental Biologics License Application for Reblozyl luspatercept-aamt for the treatment of anemia in adults with non-transfusion dependent beta thalassemia.
The company said the FDA has set a Prescription Drug User Fee Act goal date of March 27, 2022.
Bristol Myers also said the European Medicines Agency has validated the Type II variation for Reblozyl in NTD beta thalassemia. Reblozyl is being co-developed and co-commercialized with Merck & Co. Inc. following Merck's recent acquisition of Acceleron Pharma Inc.
These applications were based on safety and efficacy results from a Phase 2 study evaluating Reblozyl plus best supportive care in patients with NTD beta thalassemia.
Write to Chris Wack at chris.wack@wsj.com
(END) Dow Jones Newswires
December 03, 2021 07:31 ET (12:31 GMT)
Copyright (c) 2021 Dow Jones & Company, Inc.
1 Year Bristol Myers Squibb Chart |
1 Month Bristol Myers Squibb Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions